Lineage Cell Therapeutics (LCTX) investor relations material

Mission and platform overview

• Focus on pioneering allogeneic cell therapies using directed differentiation and transplantation to treat serious diseases.

• Proprietary AlloSCOPET platform enables scalable, consistent, off-the-shelf cell therapy production.

• Platform supports production of over 200 human cell types, with validated processes for purity, potency, and scalability.

• Internal cGMP facility with multiple clean rooms and a staff of over 50 ensures quality and reproducibility.

• Over 375 issued and pending patents protect technology and processes.

Key partnerships and financials

• Global partnership with Roche/Genentech for OpRegen, with up to $670M in milestones and double-digit royalties.

• Preclinical collaboration with William Demant Invest for Resonance, with up to $12M in funding.

• Additional service agreement with Genentech in 2024 to support OpRegen clinical and manufacturing activities.

• Strong financial position with $55.8M in cash as of December 2025, plus $5.4M from warrant exercises in March 2026.

OpRegen (RPE cell therapy for dry AMD)

• OpRegen is a one-time RPE cell transplant for dry AMD with geographic atrophy, aiming to restore retinal structure and function.

• Phase 1/2a trial showed sustained visual acuity gains and structural retinal improvements up to 36 months, especially in patients with extensive bleb coverage.

• No cases of rejection reported; well-tolerated with anatomical and functional benefits persisting at 3 years.

• Ongoing GAlette Phase 2a study, sponsored by Genentech, enrolling up to 60 patients to evaluate safety and efficacy.

• Fast Track and RMAT designations from FDA; potential for broader retinal disease applications.